Skip to main
  1. Stocks
  2. Arcus Biosciences
  3. Forecast
RCUS

Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences (RCUS) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Arcus Biosciences is viewed favorably because the totality of ARC-20 and PEAK-1-linked data suggests casdatifan could be a differentiated, potentially best-in-class HIF-2α backbone in ccRCC, with 44% ORR and 14.5-month mPFS in 2L cas + cabo, 50% cORR and 69% 12-month PFS in 1L cas + zim, and no unexpected safety signals. The outlook is further supported by a dense 2027 catalyst slate, including more mature OS data for cas + cabo, additional readthrough for PEAK-20 and PEAK-21, and early efficacy from combinations with ivonescimab and tivozanib, which could broaden the commercial opportunity across treatment lines. Beyond oncology, quemliclustat, AB102, and other immunology assets add optionality, while the recent financing caused dilution but did not alter the core thesis that Arcus has multiple shots on goal with meaningful strategic partnership interest.

Bears say

Arcus Biosciences is advancing Ph 3 combination trials before completing dose exploration, creating execution risk that the selected dose could leave efficacy on the table, fail to match bidaily administration results, or produce unexpected toxicities. Its use of EPO suppression as a competitive biomarker is also unproven, because the link to tumor response has not been rigorously tested, weakening confidence in the clinical thesis. The company’s heavy concentration in the adenosine pathway adds further downside if efficacy disappoints or safety liabilities emerge, while setbacks in competing adenosine therapies could still undermine the broader market narrative and forecast assumptions.

Arcus Biosciences (RCUS) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcus Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Arcus Biosciences (RCUS) Analyst Forecast & Price Prediction

Get the latest Arcus Biosciences (RCUS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcus Biosciences (RCUS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcus Biosciences (RCUS) Forecast

Analysts have given Arcus Biosciences (RCUS) a Buy based on their latest research and market trends.

According to 11 analysts, Arcus Biosciences (RCUS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcus Biosciences (RCUS)


Arcus Biosciences (RCUS) Analyst Forecast & Price Prediction

Get the latest Arcus Biosciences (RCUS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Arcus Biosciences (RCUS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RCUS stock data and trends